HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Hinken, A. C. Articles by Solaro, R. J. Search for Related Content PubMed PubMed Citation Articles by Hinken, A. C. Articles by Solaro, R. J.

REVIEW

A Dominant Role of Cardiac Molecular Motors in the Intrinsic Regulation of Ventricular Ejection and Relaxation

Aaron C. Hinken and R. John Solaro

Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, Illinois solarorj{at}uic.edu

	Abstract

 
Molecular motors housed in myosins of the thick filament react with thin-filament actins and promote force and shortening in the sarcomeres. However, other actions of these motors sustain sarcomeric activation by cooperative feedback mechanisms in which the actin-myosin interaction promotes thin-filament activation. Mechanical feedback also affects the actin-myosin interaction. We discuss current concepts of how these relatively under-appreciated actions of molecular motors are responsible for modulation of the ejection time and isovolumic relaxation in the beating heart.

	Introduction

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
In this review, we consider novel and, in our judgment, under-appreciated aspects of the role of sarcomeric myosin motors (cross bridges) in regulation of the heart beat. Relatively recent and compelling evidence has substantially expanded the limited textbook view of the role of cross bridges in the heart beat and in regulation of contractility. One aspect of this textbook view is that cross bridges react with actin and undergo state transitions powered by the free energy of MgATP hydrolysis that lead to a mechanical transition impelling thin filaments toward the center of the sarcomere. A second textbook view is that the actin cross-bridge reaction is inhibited at diastolic levels of sarcoplasmic Ca²⁺ and released from this inhibition when Ca²⁺ concentration increases in the sarcomeric space and Ca²⁺ binds to troponin C (cTnC). In basal metabolic states, not all available cross bridges are engaged in the actin-myosin interaction, and thus a third textbook view is that major control of contractility occurs with variations in the number of cross bridges engaged in the force-generating reaction with thin filaments. In this perspective, the level of contractility is governed largely by the amounts and rates of movements of Ca²⁺ to and from the sarcomeres.

Our expanded view of the role of the molecular motors in the heart beat includes processes intrinsic to the sarcomeres that are significant in sustaining myocardial stiffness during ejection and determining the rate of isovolumic relaxation. We discuss evidence indicating that these cooperative and mechanical feedback mechanisms are intrinsic to the sarcomeres and do not directly depend on membrane-controlled fluxes of Ca²⁺. We think this perspective of regulation of systolic mechanics and relaxation reorients thinking with regard to regulation of cardiac function from a focus on cellular Ca²⁺ fluxes to a focus on regulation of processes at the level of the sarcomeres. Central to these regulatory processes is a role of cardiac molecular motors beyond simple promotion of force generation and shortening. It is now evident that, following the triggering of activation by Ca²⁺ binding to cTnC, molecular motors are actively engaged in inducing and sustaining activation of the thin filaments. Moreover, the strain on active cross bridges, which occurs during ejection, and the rates of detachment of cross bridges are also important elements in determining the duration of systole and the rate of isovolumic relaxation. We discuss evidence that the kinetics of these sarcomeric processes are rate limiting during the cardiac cycle and modified by phosphorylation of regulatory proteins, especially cardiac myosin binding protein C (MyBP-C) and the thin-filament regulatory protein cardiac troponin I (cTnI). Finally, discussion is provided regarding evidence that the kinetics of molecular motors by drugs targeted to myosin represents a novel therapeutic approach in treatment of heart failure.

	Structure and Regulation of Cardiac Molecular Motor Activity

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
The molecular motor of heart muscle is a highly asymmetrical protein consisting of two myosin heavy chains (MHCs) (FIGURE 1) and two pairs of myosin light chains (FIGURE 1 illustrates one MHC). The MHC has a globular head, containing both the actin binding site and the ATP binding and catalyzing site at the NH₂ terminus of the protein. An -helical COOH-terminal tail interacts with another MHC in a coiled-coil motif that combines with rod portions of neighboring myosins to form the thick-filament backbone. There are two types of MHC expressed in mammalian myocardium, -MHC and ß-MHC, existing as dimers first described by Hoh et al. (16) and termed V₁, V₂, and V₃. -MHC generates about three times higher actin-activated ATPase activities, maximal filament sliding velocity, and greater peak power output than those preparations containing ß-MHC (4, 5, 13, 35, 37, 41, 47, 66, 67). -MHC, however, has been reported to produce twice the cross-bridge force per ATPase cycle as -MHC, meaning it consumes less energy to maintain a given force or a lower tension cost (12, 17, 31, 50, 58). Expression of these isoforms is species dependent and both developmentally and hormonally regulated (33) with V₃ myosin, a ß ß-MHC homodimer predominately expressed during early development of all mammals and remaining high throughout life in humans and other large mammals. The V₁ cardiac myosin, a -MHC homodimer, predominates in mammalian hearts soon after birth and remains high throughout life in rats and mice (11).

View larger version (34K): [in this window] [in a new window]   FIGURE 1. Schematic illustrating the state of cross bridges in the cycle from rest to active states Thin-filament actins are shown with regulatory proteins tropomyosin (Tm) and troponin (Tn) with the Ca2+-binding unit (cTnC) shown in red, the Tm-binding unit (cTnT) in blue, and the inhibitory unit (cTnI) in green. Thick-filament cross bridges (XB) are shown with myosin heavy chain (MHC) and light chains (LC) together with myosin binding protein C (MyBP-C) and titin. See text for further description of the cycle and interpretation of the rate constants.

	Thick- and Thin-Filament States in the Cardiac Cycle

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
As depicted in FIGURE 1,myosin cross bridges cyclically interact with actin in a process coupled to the hydrolysis of ATP, which drives myocardial force generation and contraction. Cross bridges are initially in a weakly bound, non-force-generating "rest" state (state 1, FIGURE 1) during diastole. FIGURE 1 shows a thin-filament regulatory unit (RU) consisting of actin-troponin-tropomyosin in a 7:1:1 ratio. Troponin (Tn) is a heterotrimer consisting of cTnC, cTnI, and cTnT. In the rest state, there is no Ca²⁺ bound to regulatory sites on cTnC; cTnI forms a complex with both actin and cTnT and thus reduces the reactivity of actin for myosin and holds tropomyosin in a position that blocks the cross-bridge binding sites on actin (30, 68).

The triggering of force generation and contraction is governed by Ca²⁺ fluxes determined by the dynamics of electrochemical coupling of Ca²⁺ release and Ca²⁺ binding to cTnC. Cross bridges and thin filaments now enter into a transition state (state 2; FIGURE 1) determined by the on (k_Ca) and off rates (k_Ca–1) for Ca²⁺ exchange with cTnC. This "transition" state involves altered interactions between TnI and actin, increased binding of cTnI to cTnC, and a cTnT-dependent shift in Tm from its blocking position on the thin filament. These changes in the thin filament permit a shift in cross bridges toward strongly bound, force-generating states (state 3; FIGURE 1). The transition state is homologous to other cross-bridge models whereby a myosin head has a full compliment of ATP hydrolysis products (ADP and P_i) bound and Ca²⁺ bound at the thin filament. The state 2-to-state 3 transition (FIGURE 1; k_XB and k_XB-1) from weak-binding, non-force-generating cross bridges to strong-binding, force-generating states is regulated by the kinetics inherent to cross bridges. The rate-limiting kinetic transition determining the shift toward the "active" state appears to be dependent on the load on the muscle (18) with loads near peak power output (similar to those encountered during ejection) determined by the release of P_i (15) and loads more near isometric (such as occur during isovolumic contraction and relaxation) determined by ADP release (69). An important aspect of state 3 is that strongly bound cross bridges also induce cooperative activation of the thin filament by an increase in the affinity of cTnC for Ca²⁺ (10, 29, 43). In addition to this cooperative process within an RU, there is also a cooperative activation of near neighbor RU transmitted through end-to-end interactions between contiguous Tm strands and possibly through actin-actin interactions (as reviewed in Refs. 9, 40, 63). This mechanism of propagated activation appears to be particularly important in cardiac compared with skeletal muscle, where relatively small changes in strongly bound cross bridges have significant effects on Ca²⁺ sensitivity of force and cross-bridge kinetics (6, 7).

A consequence of these cooperative mechanisms is illustrated by state 4 in FIGURE 1, which indicates a population of cross bridges that remain in the active, force-generating state despite the loss of bound Ca²⁺. As discussed below, the lifetime of state 4 is an important determinant of the duration of ejection. Inasmuch as the kinetic transition between states 3 and 4 (and state 2 to 3 to some extent) is dependent on cross-bridge feedback, mechanisms that alter the number of active cross bridges will alter this transition. Processes that may potentially modify the number of active cross bridges include the sarcomere length, as determined by the end-diastolic volume, the strength of the interaction energies determining cooperativity within and between RU, and stretch-induced activation (54). Mechanical feedback associated with sarcomere shortening also controls the transition from the strong binding state 4 to the weak binding state 1, thereby determining the duration of state 4. The mechanical feedback, which is indicated as a unidirectional rate constant (k_vel) in FIGURE 1, occurs as a result of strain imposed on active cross bridges with shortening, a process known as shortening-induced deactivation (20, 36, 39). Thus the balance of the intensity of the cooperative mechanisms, which promote the transition to state 4, and the mechanical feedback, which promotes dissipation of state 4, determine the population of cross bridges in state 4. Therefore, these mechanisms are likely to be important determinants of the time to the end of systole.

Another more controversial possibility to increase cross-bridge availability permitting feedback would be to allow individual cross bridges to interact with the thin filament multiple times during activation. The cross-bridge cycle described by FIGURE 1 assumes cross bridges driving cardiac pump function are tightly coupled to ATP hydrolysis (i.e., one ATP per cross-bridge cycle). However, questions remain as to the validity of this assertion. Evidence for a more loosely coupled system comes from observations by the Yanagida laboratory (23) and Lombardi et al. (32) that a single cross bridge can move actin many times the length of a single cross-bridge swing on an individual ATP and that cross bridges can reprime following a power stroke without binding additional ATP, respectively. In agreement, based on experimental data concerning length-tension area (analogous to pressure-volume area) vs. oxygen consumption, Taylor et al. (62) concluded the cross bridge-to-ATP ratio may be variable with tightly coupled usage at high loads becoming more loosely coupled at low loads where muscle may shorten (reviewed in Ref. 57).

	A Dominant Role of Processes Involving Cardiac Molecular Motors in Left Ventricular Ejection and Isovolumic Relaxation

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
Ultimately, the reactions of molecular motors in the left ventricle (FIGURE 1) are responsible for the ejection of blood into the peripheral circulation. During a beat of the left ventricle, pressure rises for a time with no change in ventricular volume and limited internal shortening of the sarcomeres. During this phase, cross bridges are recruited into action as Ca²⁺ rises in the sarcomeric space. When the aortic valve opens, ejection begins and the sarcomeres shorten. In this phase, cross bridges impel the thin filaments toward the center of the sarcomere. Shortening imposes a strain on reacting cross bridges and alters the kinetics of the actin-myosin reaction. As systole progresses and blood flows to the periphery, left ventricle pressure falls, the valve closes, pressure falls with no change in ventricular volume, and the strain dependence of actin cross-bridge kinetics is greatly relieved. Unfortunately, much of our understanding of the cellular mechanisms governing these processes (such as the dynamics of excitation contraction coupling and relaxation) is based on determinations of intracellular Ca²⁺ and mechanics with myocytes shortening against zero loads or not shortening at all. In the following, we expand governance of these processes to include prominent, intrinsic sarcomeric regulation of these processes and alterations occurring with changes in load.

Differences in kinetics of sarcomeric-bound Ca²⁺ and pressure during a heart beat
A major challenge in the investigation of molecular control mechanisms in regulation of the heart beat is how to connect the action of the cardiac molecular motors to global ventricular function. These actions include state transitions leading to development of force and shortening, promotion of the activated state of thin filaments, response to the prevailing pre-load and afterload, and the relative amounts of Ca²⁺-bound to cTnC (related to contractility) that ensures efficient ejection of the blood added to the ventricle during diastole. FIGURE 2 depicts the time course of Ca²⁺ bound to cTnC in a region of the A band of sarcomeres at various time points during pressure changes during a beat of the left ventricle. The figure illustrates our perception of the state of the A-band region at various time points during the beat. Estimation of Ca²⁺ binding to the thin filaments is based on a computational model of Burkoff (2), which is in general agreement with experimental findings (60) and other models of transitions in thin-filament RUs during left ventricular pressure development in a beat of the heart (29). These models are driven by experimental determinations of the transient change in Ca²⁺ (29, 44) and by determinations of kinetics and steady-state binding of Ca²⁺ to Tn in myofilaments (43, 49). The estimate is also based on studies by Peterson et al. (44), who applied a mechanical assay to determine the time course of the amounts of Ca²⁺ bound to cTnC, and by Ishikawa et al. (19), who used a quick-release protocol and intracellular aequorin to determine cTnC-bound Ca²⁺. These studies both demonstrated that the fall in thin-filament-bound Ca²⁺ precedes the fall in force in an isometric twitch of heart muscle.

View larger version (42K): [in this window] [in a new window]   FIGURE 2. Relation between Ca2+ bound to cardiac thin filaments (Ca2+-Tn-Tm-Actin) and left ventricular pressure (LVP) in a beat of the heart Note that Ca2+ bound to the thin filament wanes at a time when ejection is still underway. See text for further description of intrinsic sarcomeric mechanism sustaining ejection independent of bound Ca2+ and determining rate of isovolumic relaxation. Computation of bound Ca2+ based on Burkhoff (2).

Processes intrinsic to the sarcomere control systolic mechanics and relaxation
Consideration of the change in the state of the A-band sarcomeric proteins during the transition from diastole to systole and the return to diastole during a heart beat serves to describe the interplay between control mechanisms extrinsic (such as membrane-dependent regulation of Ca²⁺ fluxes) and mechanisms intrinsic to the sarcomere. In the diastolic state, cross bridges are either blocked from reacting with actin or in a weak, non-force-generating state (FIGURE 1). The molecular motors of the heart are not completely passive in diastole in that they are likely to sense the preload. There is evidence that the state of stretch of the myocardium at the end of diastole is transmitted to the cross bridges by titin, which is responsible for the passive force of the myocyte (8). Pre-load determines the strain on titin, and it is plausible (although not fully documented) that the net effect of the longitudinal and radial strain on titin alters interfilament spacing or provides a signal acting through a titin-MyBP-C-cross-bridge interaction by which the molecular motors sense sarcomere length (8). In general, it has been thought that the motors sense sarcomere length via a length-dependent change in interfilament spacing, which in effect alters the local concentration of cross bridges at the actin binding sites and thereby alters the myofilament response to Ca²⁺ (25, 26, 38). This "length-dependent activation" of the sarcomeres provides the cellular mechanism for the Frank-Starling law. Yet the theory that length dependence of activation is well correlated with changes in interfilament spacing has not stood the test of direct determination of the interfilament spacing by X-ray diffraction (25, 26).

With release of Ca²⁺ into the sarcomeric space, Ca²⁺ binds to cTnC, and systole begins. The transient change of intracellular Ca²⁺ in the sarcomeric space, as detected by intracellular fluorescent probes, demonstrates only ~2% of the total cellular Ca²⁺ that moves from the extracellular space and sarcoplasmic reticulum (SR) and back during a heart beat (52). Thus the bulk of these Ca²⁺ ions is bound to buffers including TnC and other regulatory Ca²⁺-binding proteins such as calmodulin (64). With the rise in cTnC-bound Ca²⁺, which is shown in FIGURE 2, cross bridges make the transition from the blocked or weak binding state to a strong force-generating state. A reasonable estimate is that ~20–25% of available cross bridges are recruited into the systolic state during resting levels of cardiac output (24). The reactions of these cross bridges generate the wall tension responsible for the rising phase of left ventricular pressure; shortening is limited until sufficient pressure is generated to open the aortic valve.

Removal of Ca²⁺ from the sarcoplasm by the SR pump and the Na⁺/Ca²⁺ exchanger sets into motion a process whereby Ca²⁺ is released from cTnC, and this is in part responsible for the decay in Ca²⁺ bound to the thin filaments. However, as illustrated in FIGURE 2, this fall in thin-filament Ca²⁺ binding precedes the fall in left ventricular pressure, thus indicating that the actin cross-bridge reactions are sustained even in the face of a decline in Ca²⁺-dependent activation. Moreover, at the time the aortic valve opens, cooperative mechanisms in which thin filament RUs remain active without Ca²⁺ bound sustain ejection (FIGURE 2). Computational models indicate that this state occurs by cooperative mechanisms within an RU in which cross-bridge binding to the thin filament increases the affinity of cTnC for Ca²⁺ (step 4 in FIGURE 1) and by near-neighbor cooperative mechanisms acting longitudinally along the thin filament (9, 48). As ejection proceeds against the afterload, cross bridges enter into a new state in which the strain imposed by shortening promotes release of ADP from the cross bridges, an increase in ATP turnover, and an increase in cross-bridge detachment rate. The effect of strain on cross bridges is well accepted to affect nucleotide binding. For example, in slow skeletal muscle, ADP release is sensitive to the load; the lighter the load, the greater the shortening velocity, the faster the release of ADP, and the faster the ATP turnover (51). This strain dependence of cross-bridge kinetics is the basis for the Fenn effect. This "mechanical feedback" thus promotes the transition of cross bridges from strong to weak binding states (step 4 in FIGURE 1) and lowers the affinity of cTnC for Ca²⁺. As a result, rate of loss of bound Ca²⁺ is enhanced. Thus systolic mechanics reflect a balance between cooperative activation of thin filaments and shortening-induced deactivation (29). It is evident that the dissipation of the cooperative activation is relatively slow. In shortening from a long to a short length, Chandra and Campbell (3) suggest that the sarcomeres "remember the higher force attained at the longer length" and shortening (ejection) is prolonged in comparison to the situation with no cooperative mechanisms. The kinetics of the cross-bridge cycle and the relative time the cross bridges are strongly bound, especially the rate of detachment of cross bridges, is also an important determinant of the time in ejection and the isovolumic relaxation rate.

Mechanisms at the level of the sarcomere that affect relaxation include the dissipation of the cooperative activation of the thin filament and forward detachment of cross bridges as ATP binding to cross bridges reestablishes the actin-myosin-ADP-P_i weak binding state (state 1 in FIGURE 1). A third mechanism is a strain-dependent reversal of the power stroke transition from the actin-myosin-ADP state to the actin-myosin-ADP-P_i state (a transition from state 3 to state 2, as illustrated in FIGURE 1). In the case of myofibril preparations, relaxation is accelerated by small stretches and by increased P_i concentration (46). These common effects have been interpreted by Poggesi et al.(46) to indicate that, in relaxation, both P_i binding to cross bridges and altered cross-bridge strain during relaxation may result in reversal of the power stroke. If a significant number of the cross bridges undergo this reversal of the power stroke, then a significant potential outcome is that weak binding cross bridges are reestablished without splitting ATP and ready to engage in the cross-bridge cycle in the next beat.

Direct tests of the relative significance of processes extrinsic to the sarcomere (Ca²⁺ uptake by the SR) and these processes intrinsic to the sarcomere indicate that the intrinsic processes can be rate limiting. For example, in the experiments of Peterson et al.(44), the derivative curve of bound Ca²⁺ fell to low levels, whereas force remained high during the onset of relaxation in an isometric twitch. This result indicates that factors other than the velocity of SR Ca²⁺ uptake are rate limiting in loaded ejections with shortening. Sys and Brutsaert (60) reached the same conclusion using a different experimental approach. On the other hand, when Peterson et al.(44) used ryanodine to slow Ca²⁺ uptake by SR, the fall in force and cTnC-bound Ca²⁺ occurred in parallel. Thus, when SR Ca²⁺ uptake is slowed down as in heart failure (45), the role of processes intrinsic to the sarcomeres becomes relatively blunted.

	Control of Cardiac Molecular Motors by Modulation of Thick- and Thin-Filament Regulatory Proteins

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
Phosphorylation of thin- and thick-filament regulatory proteins that modulate the actin-cross-bridge reaction also affect duration of ejection and relaxation. Although multiple sarcomeric proteins are modified by phosphorylation (reviewed in Refs. 24, 53), we focus here on MyBP-C and cTnI inasmuch as the state of these proteins has been reported to affect systolic mechanics. Both proteins are phosphorylated by protein kinase A at sites unique to the cardiac variants. In the case of MyBP-C, compared with controls, mouse hearts lacking cMyBP-C demonstrate a significantly abbreviated time course of systolic elastance (42). There is little change in the early phase of systole, but hearts lacking MyBP-C relax prematurely. Sarcomeres lacking MyBP-C also have faster unloaded shortening velocity than controls (42). Importantly, PKA-dependent phosphorylation of MyBP-C, which occurs at a site that interacts with myosin S2, mimics the effects of its ablation (55). Thus it is apparent and likely that the state of MyBP-C modifies the transmission of force across the sarcomere as well as shortening-induced deactivation. This finding may be of significance regarding the pathology of mutations in MyBP-C, which are a common cause of familial cardiomyopathy (1).

Among TnI variants, cTnI is unique in having an NH₂-terminal extension of 30 amino acids that contain PKA-dependent phosphorylation sites. Phosphorylation of these sites appears pivotal in the positive inotropic response to ß-adrenergic stimulation (22) and to changes in frequency (61). However, the demonstration of both of these effects is most evident in auxotonically loaded, ejecting hearts and much less evident in isovolumic hearts, isometric muscle preparations, or unloaded isolated myocytes. The increases in ejection indexes, such as stroke work and the end-systolic pressure-volume relation, are significantly blunted in hearts expressing slow skeletal TnI (which lacks the PKA sites) in place of cTnI (22). However, myocytes from these hearts or isovolumic hearts demonstrated nearly the same inotropic responses to ß-adrenergic stimulation as the controls. Phosphorylation of cTnI has also been reported to increase unloaded shortening velocity and power generation by isolated, skinned cardiac myocytes (14) and to enhance the effect of sarcomere length on force-Ca²⁺ relation (26). Taken together, these results indicate a significant involvement of the cTnI phosphorylation in cardiac systolic mechanics and relaxation in response to ß-adrenergic stimulation by its effects on the cooperative activation and mechanical feedback.

Hearts of transgenic mice (TG-cTnIDD) expressing cTnI, in which the PKA-targeted Ser are mutated to Asp as a phosphorylation mimetic, also show responses to increases in frequency, indicating an effect of cTnI phosphorylation on rate-dependent increases in systolic function (61). Moreover, there was a prolonged relaxation associated with increased afterload in nontransgenic control hearts beating in situ when compared to the TG-cTnI-DD hearts. This difference was not evident when the hearts were treated with isoproterenol. As with the studies on the TG-ssTnI hearts, frequency-dependent responses in isometric trabeculae from the TG-cTnIDD hearts did not demonstrate differences from controls (61). These studies reinforce the role of cTnI phosphorylation on systolic function and relaxation kinetics and also indicate that the mechanism is revealed when cross bridges function against a load as in the ejecting ventricles. It has been reported that that there is a diminished TnI phosphorylation in that, which is likely to be an important mechanism in the blunted force-frequency relation of failing human hearts.

	Novel Pharmaceutical Therapies Targeting Molecular Motors

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 
Translation of the detailed understanding of sarcomeric regulation to therapeutics is an important research objective, and there is evidence that pharmacological modification of molecular motors may be useful as a therapeutic approach for heart failure. One aim has been the discovery of small molecules that directly modify sarcomeric proteins and improve cardiac function. Early phases of the search for such compounds that enhance myofilament sensitivity to Ca²⁺ targeted thin-filament proteins. Examples of these agents are levosimendan and EMD 57033, which bind to cTnC, and pimobendan, which promotes Ca²⁺ binding to cTnC. These agents improves systolic function in animal models of heart failure (as reviewed in Ref. 21), and levosimendan and pimobendan have progressed into clinical use. More recently, there has been a search for agents directly affecting the molecular motors of the heart. Although further studies are required to establish the value of these agents in human therapeutic application, the initial data are promising (34). It is apparent that modification of the myosin by these agents prolongs systolic ejection. This indicates that these agents alter the balance of cooperative mechanisms and shortening induced deactivation such that systolic mechanics are enhanced. Whether modification of troponin and/or MyBP-C by drugs may also affect this balance appears possible but has not been investigated explicitly.

	References

Top Introduction Structure and Regulation of... Thick- and Thin-Filament States... A Dominant Role of... Control of Cardiac Molecular... Novel Pharmaceutical Therapies... References

 

1. BonneG, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Beckman J, Weissenbach J, Vosberg HP, Fiszman M, Komajda M, Schwartz K. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 11: 438–440, 1995.[CrossRef][ISI][Medline]
2. BurkhoffD. Explaining load dependence of ventricular contractile properties with a model of excitation-contraction coupling. J Mol Cell Cardiol 26: 959–978, 1994.[CrossRef][ISI][Medline]
3. CampbellKB, Chandra M. Functions of Stretch Activation in Heart Muscle. J Gen Physiol 127: 89–94, 2006.[Free Full Text]
4. De TombePP, ter Keurs EDJ. An internal viscous element limits unloaded velocity of sarcomere shortening in rat cardiac trabeculae. J Physiol 454: 619–642, 1992.[Abstract/Free Full Text]
5. FitzsimmonsDP, Patel JR, Moss RL. Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium. J Physiol 513: 171–183, 1998.[Abstract/Free Full Text]
6. FitzsimonsDP, Moss RL. Strong binding of myosin modulates length-dependent Ca²⁺ activation of rat ventricular myocytes. Circ Res 83: 602–607, 1998.[Abstract/Free Full Text]
7. FitzsimonsDP, Patel JR, Moss RL. Cross-bridge interaction kinetics in rat myocardium are accelerated by strong binding of myosin to the thin filament. J Physiol 530: 263–272, 2001.[Abstract/Free Full Text]
8. FukudaN, Granzier HL. Titin/connectin-based modulation of the Frank-Starling mechanism of the heart. J Muscle Res Cell Motil 26: 319–323, 2005.[CrossRef][ISI][Medline]
9. GordonAM, Homsher E, Regnier M. Regulation of Contraction in Striated Muscle. Physiol Rev 80: 853–924, 2000.[Abstract/Free Full Text]
10. GordonAM, Ridgway EB. Cross-bridges affect both TnC structure and calcium affinity in muscle fibers. Adv Exp Med Biol 332: 183–192; discussion 192–184, 1993.[Medline]
11. HamiltonN, Ianuzzo CD. Contractile and calcium regulating capacities of myocardia of different sized mammals scale with resting heart rate. Mol Cell Biochem 106: 133–141, 1991.[ISI][Medline]
12. HarrisDE, Work SS, Wright RK, Alpert NR, Warshaw DM. Smooth, cardiac, and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil 15: 11–19, 1994.[CrossRef][ISI][Medline]
13. HerronTJ, Korte FS, McDonald KS. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 281: H1217–H1222, 2001.[Abstract/Free Full Text]
14. HerronTJ, Korte FS, McDonald KS. Power output is increased after phosphorylation of myofibrillar proteins in rat skinned cardiac myocytes. Circ Res 89: 1184–1190, 2001.[Abstract/Free Full Text]
15. HinkenAC, McDonald KS. Inorganic phosphate speeds loading shortening and increases power output in rat skinned cardiac myocytes. Am J Physiol Cell Physiol 287: C500–C507, 2004.[Abstract/Free Full Text]
16. HohJFY, McGrath PA, Hale PT. Electrophoretic analysis of multiple forms of rat cardiac myosin: effects of hypophysectomy and thyroxine replacement. J Mol Cell Cardiol 10: 1053–1076, 1977.[CrossRef][ISI]
17. HolubarschC, Goulette RP, Litten RZ, Martin BJ, Mulieri LA, Alpert NR. The economy of isometric force development, myosin isozyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ Res 56: 78–86, 1985.[Abstract/Free Full Text]
18. HomsherE, Lacktis J, Regnier M. Strain-dependent modulation of phosphate transients in rabbit skeletal muscle fibers. Biophys J 72: 1780–1791, 1997.[ISI][Medline]
19. IshikawaT, OUchi J, Mochizuki S, Kurihara S. Evaluation of the cross-bridge-dependent change in the Ca²⁺ affinity of troponin C in aequorin-injected ferret ventriculr muscles. Cell Calcium 37: 153–162, 2005.[CrossRef][ISI][Medline]
20. IwamotoI. Thin filament cooperativity as a major determinant of shortening velocity in skeletal muscle fibers. Biophys J 74: 1452–1464, 1998.[ISI][Medline]
21. KassDA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113: 305–315, 2006.[Free Full Text]
22. KentishJC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and cossbridge cycle kinetics in mouse ventricular muscle. Circ Res 88: 1059–1065, 2001.[Abstract/Free Full Text]
23. KitamuraK, Tokunaga M, Iwane AH, Yanagida T. A single myosin head moves along an actin filament with regular steps of 5.3 nanometres. Nature 397: 129, 1999.[CrossRef][Medline]
24. KobayashiT, Solaro RJ. Calcium, thin filaments, and the intregrative biology of cardiac contractility. Annu Rev Physiol 67: 39–67, 2005.[CrossRef][ISI][Medline]
25. KonhilasJP, Irving TC, de Tombe PP. Frank-Starling law of the heart and the cellular mechanisms of length-dependent activation. Pflügers Arch 445: 305–310, 2002.[CrossRef][ISI][Medline]
26. KonhilasJP, Irving TC, Wolska BM, Jweied EE, Martin AF, Solaro RJ, de Tombe PP. Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing. J Physiol 547: 951–961, 2003.[Abstract/Free Full Text]
27. KorteFS, McDonald KS, Harris SP, Moss RL. Loaded shortening, power output, and rate of force redevelopment are increased with knockout of cardiac myosin binding protein-C. Circ Res 93: 752–758, 2003.[Abstract/Free Full Text]
28. KunstG, Kress KR, Gruen M, Uttenweiler D, Gautel M, Fink RHA. Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ Res 86: 51–58, 2000.[Abstract/Free Full Text]
29. Landesberg A. End-systolic pressure-volume relationship and intracellular control of contraction. Am J Physiol Heart Circ Physiol 270: H338–H349, 1996.[Abstract/Free Full Text]
30. LehmanW, Craig R, Vibert P. Ca²⁺-induced tropomyosin movement in Limulus thin filaments revealed by three-dimensional reconstruction. Nature 368: 65–67, 1994.[CrossRef][Medline]
31. LoiselleDS, Wendt IR, Hoh JFY. Energetic consequences of thyroid-modulated shifts in ventricular isomyosin distribution in the rat. J Muscle Res Cell Motil 3: 5–23, 1982.[CrossRef][ISI][Medline]
32. LombardiV, Piazzesi G, Linari M. Rapid regeneration of the actin-myosin power stroke in contracting muscle. Nature 355: 638–641, 1992.[CrossRef][Medline]
33. LompreAM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular alpha- and beta-myosin heavy chain genes is developmentally and hormonally regulated. J Biol Chem 259: 6437–6446, 1984.[Abstract/Free Full Text]
34. MalikF, Teerlink JR, Escandon RD, Clark CP, Wolff AA. The selective cardiac myosin activator, CK-1827452, a calcium-independent inotrope, increases left ventricular systolic function by increasing ejection time rather than the velocity of contraction (Abstract). Circulation 114: II-441, 2006.
35. MartinAF, Pagani ED, Solaro RJ. Thyroxine-induced redistribution of isoenzymes of rabbit ventricular myosin. Circ Res 50: 117–124, 1982.[Free Full Text]
36. MartynDA, Rondinone JF, Huntsman LL. Myocardial segment velocity at a low load: time, length, and calcium dependence. Am J Physiol Heart Circ Physiol 13: H708–H714, 1983.
37. McDonaldKS, Herron TJ. It takes "heart" to win: what makes the heart powerful? News Physiol Sci 17: 185–190, 2002.[Abstract/Free Full Text]
38. McDonaldKS, Moss RL. Osmotic compression of single cardiac myocytes reverses the reduction in Ca²⁺ sensitivity of tension observed at short sarcomere length. Circ Res 77: 199–205, 1995.[Abstract/Free Full Text]
39. McDonaldKS, Moss RL. Strongly binding myosin cross-bridges regulate loaded shortening and power output in cardiac myocytes. Circ Res 87: 768–773, 2000.[Abstract/Free Full Text]
40. MossRL, Razumova M, Fitzsimons DP. Myosin crossbridge activation of cardiac thin filaments: implications for myocardial function in health and disease. Circ Res 94: 1290–1300, 2004.[Abstract/Free Full Text]
41. PaganiED, Julian FJ. Rabbit papillary muscle myosin isozymes and the velocity of muscle shortening. Circ Res 54: 586–594, 1984.[Abstract/Free Full Text]
42. PalmerBM, Georgakopoulos D, Janssen PM, Wang Y, Alpert NR, Belardi DF, Harris SP, Moss RL, Burgon PG, Seidman CE, Seidman JG, Maughan DW, Kass DA. Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening. Circ Res 94: 1249–1255, 2004.[Abstract/Free Full Text]
43. PanBS, Solaro RJ. Calcium-binding properties of troponin C in detergent-skinned heart muscle fibers. J Biol Chem 262: 7839–7849, 1987.[Abstract/Free Full Text]
44. PetersonJN, Hunter WC, Berman MR. Estimated time course of Ca²⁺ bound to troponin C during relaxation in isolated cardiac muscle. Am J Physiol Heart Circ Physiol 260: H1013–H1024, 1991.[Abstract/Free Full Text]
45. PiacentinoV, III, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 92: 651–658, 2003.[Abstract/Free Full Text]
46. PoggesiC, Tesi C, Stehle R. Sarcomeric determinants of striated muscle relaxation kinetics. Pflügers Arch 449: 505–517, 2005.[CrossRef][ISI][Medline]
47. PopeB, Hoh JFY, Weeds A. The ATPase activities of rat cardiac myosin isoenzymes. FEBS Lett 118: 205–208, 1980.[CrossRef][ISI][Medline]
48. RasumovaMV, Bukatina AE, Campbell KB. Different myofilament nearest-neighbor interactions have distinctive effects on contractile behavior. Biophys J 78: 3120–3137, 2000.[ISI][Medline]
49. RobertsonSP, Johnson JD, Potter JD. The time-course of Ca²⁺exchange with calmodulin, troponin, parvablumin, and myosin in response to transient increases in Ca²⁺. Biophys J 34: 559–569, 1981.[ISI][Medline]
50. RundellVL, Geenen DL, Buttrick PM, de Tombe PP. Depressed cardiac tension cost in experimental diabetes is due to altered myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 287: H408–H413, 2004.[Abstract/Free Full Text]
51. ShirakawaI, Chaen S, Bagshaw CR, Sugi H. Measurement of nucleotide exchange rate constants in single rabbit soleus myofibrils during shortening and lengthening using a fluorescent ATP analog. Biophys J 78: 918–926, 2000.[ISI][Medline]
52. SipidoKR, Wier WG. Flux of Ca²⁺ across the sarcoplasmic reticulum of guinea-pig cardiac cells during excitation-contraction coupling. J Physiol 435: 605–630, 1991.[Abstract/Free Full Text]
53. SolaroRJ. Modulation of Cardiac Myofilament Activity by Protein Phosphorylation. New York: Oxford Univ. Press, 2001.
54. StelzerJE, Moss RL. Contributions of stretch activation to length-dependent contraction in murine myocardium. J Gen Physiol 128: 461–471, 2006.[Abstract/Free Full Text]
55. StelzerJE, Patel JR, Moss RL. Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ Res 99: 884–890, 2006.[Abstract/Free Full Text]
56. StephensonGM, Stephenson DG. Endongenous MLC2 phosphorylation and Ca²⁺-activated force in mechanically skinned skeletal muscle fibres of the rat. Pflügers Arch 424: 30–38, 1993.[CrossRef][ISI][Medline]
57. SugaH. Mechanoenergetic estimation of multiple cross-bridge steps per ATP in a beating heart. Jpn J Physiol 54: 103–108, 2004.[CrossRef][ISI][Medline]
58. SugiuraS, Kobayakawa N, Fujita H, Yamashita H, Momomura S, Chaen S, Omata M, Sugi H. Comparison of unitary displacements and forces between 2 cardiac myosin isoforms by the optical trap technique: molecular basis for cardiac adaptation. Circ Res 82: 1029–1034, 1998.[Abstract/Free Full Text]
59. SweeneyHL, Stull JT. Phosphorylation of myosin in permeabilized mammalian cardiac and skeletal muscle cells. Am J Physiol Cell Physiol 250: C657–C660, 1986.[Abstract/Free Full Text]
60. SysSU, Brutsaert DL. Determinants of force decline during relaxation in isolated cardiac muscle. Am J Physiol Heart Circ Physiol 257: H1490–H1497, 1989.[Abstract/Free Full Text]
61. TakimotoE, Soergel DG, Janssen PM, Stull LB, Kass DA, Murphy AM. Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res 94: 496–504, 2004.[Abstract/Free Full Text]
62. TaylorTW, Goto Y, Suga H. Variable cross-bridge cycling-ATP coupling accounts for cardiac mechanoenergetics. Am J Physiol Heart Circ Physiol 264: H994–H1004, 1993.[Abstract/Free Full Text]
63. TobacmanLS. Thin filament-mediated regulation of cardiac contraction. Annu Rev Physiol 58: 447–481, 1996.[CrossRef][ISI][Medline]
64. TraffordAW, Diaz ME, Eisner DA. A novel, rapid and reversible method to measure Ca buffering and time-course of total sarcoplasmic reticulum Ca content in cardiac ventricular myocytes. Pflügers Arch 437: 501–503, 1999.[CrossRef][ISI][Medline]
65. TrybusKM. Role of myosin light chains. J Muscle Res Cell Motil 15: 587–594, 1994.[CrossRef][ISI][Medline]
66. VanBurenP, Harris DE, Alpert NR, Warshaw DM. Cardiac V₁ and V₃ myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res 77: 439–444, 1995.[Abstract/Free Full Text]
67. WinegradS, Weisberg A. Isozyme specific modification of myosin ATPase by cAMP in rat heart. Circ Res 60: 384–392, 1987.[Abstract/Free Full Text]
68. XuC, Craig R, Tobacman LS, Horowitz R, Lehman W. Tropomyosin positions in regulated thin filaments revealed by cryoelectron microscophy. Biophys J 77: 985–992, 1999.[ISI][Medline]
69. ZhaoY, Kawai M. Kinetic and thermodynamic studies of the cross-bridge cycle in rabbit psoas muscle fibers. Biophys J 67: 1655–1668, 1994.[ISI][Medline]

This article has been cited by other articles:

				R. J. Solaro Multiplex Kinase Signaling Modifies Cardiac Function at the Level of Sarcomeric Proteins J. Biol. Chem., October 3, 2008; 283(40): 26829 - 26833. [Full Text] [PDF]

				K. B. Campbell, A. M. Simpson, S. G. Campbell, H. L. Granzier, and B. K. Slinker Dynamic left ventricular elastance: a model for integrating cardiac muscle contraction into ventricular pressure-volume relationships J Appl Physiol, April 1, 2008; 104(4): 958 - 975. [Abstract] [Full Text] [PDF]

				B. Iorga, N. Blaudeck, J. Solzin, A. Neulen, I. Stehle, A. J. L. Davila, G. Pfitzer, and R. Stehle Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils Cardiovasc Res, March 1, 2008; 77(4): 676 - 686. [Abstract] [Full Text] [PDF]

				A. Cammarato, C. M. Dambacher, A. F. Knowles, W. A. Kronert, R. Bodmer, K. Ocorr, and S. I. Bernstein Myosin Transducer Mutations Differentially Affect Motor Function, Myofibril Structure, and the Performance of Skeletal and Cardiac Muscles Mol. Biol. Cell, February 1, 2008; 19(2): 553 - 562. [Abstract] [Full Text] [PDF]

				K. S. McDonald Regulation of cardiac muscle contraction: how paramount are the sarcomeres? Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R961 - R962. [Full Text] [PDF]

				R. J. Solaro Nitroxyl effects on myocardium provide new insights into the significance of altered myofilament response to calcium in the regulation of contractility J. Physiol., May 1, 2007; 580(3): 697 - 697. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Hinken, A. C. Articles by Solaro, R. J. Search for Related Content PubMed PubMed Citation Articles by Hinken, A. C. Articles by Solaro, R. J.